Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both ...

Roche’s fenebrutinib, an investigational BTK inhibitor for multiple sclerosis, has received FDA acceptance for its New Drug Application under priority review for both relapsing and primary progressive MS, based on positive Phase III trials showing significant relapse reduction and disability progression delay.

This Wire brief sits within Fusion42's coverage of Biotech.